News Focus
News Focus
Replies to #94820 on Biotech Values
icon url

jbog

04/27/10 2:13 PM

#94827 RE: DewDiligence #94820

Study finds what many feared; needed savings will be elusive

Updated: April 26, 2010, 11:16 pm /

Published: April 27, 2010, 6:42 am

As more information emerges on the recent health care reform legislation, it is not surprising that analysts now believe it will cost more than people were told.

In the first report since the bill was passed, economic experts at the Department of Health and Human Services say the bill, passed only last month, will increase the costs of health care by $511 billion over the next 10 years, instead of bringing them down. That comes from the Obama administration, although the analysts involved are considered neutral, and while it represents only a 1 percent increase it's still a sobering conclusion … because it's a best-case scenario, and it's dependent on a half-trillion dollars in cuts to the Medicare program, largely through Medicare Advantage.


These cuts, projected to save $520 billion over time, would be a real blow to the elderly. Hospitals, nursing homes, hospice and home health care also would be among the hardest hit. Many observers believe Congress will ultimately flinch, thus driving the costs of care even higher. For example, if the cuts are enacted, the report projects that they would push about 15 percent of hospitals and other institutional providers into the red.

Congress never has been willing to make such cuts targeting seniors, and it's doubtful it will do that now. Without the cuts, and with the estimated increase in costs, losses would hit the trillion-dollar range.

This page has endorsed health care reform as necessary to the nation's well-being. With some 50 million Americans uninsured and costs driving toward 20 percent of gross domestic product, the nation desperately needed to address the problems of health care.

But, first and foremost, reform needed to target the costs of health care because, absent that achievement, all other reforms will be threatened. That includes one of the goals that Obama did achieve, providing coverage to 34 million Americans who now lack insurance … a gain that comes at a cost of $800 million, and without any guarantees there will be enough doctors, nurses and other resources to meet increased health care demands.

Buried in the act were a new long-term care insurance program whose premiums wrongly were double-counted as deficit reducing, and … despite the elimination of some special benefits … millions of dollars to interests in the districts of key senators and representatives. Major insurance companies already are planning premium increases based on expected health care cost increases under this plan. It's no wonder the public did not believe claims of cost-cutting.

The White House, for its part, has complained about such analyses, contending that they take too little notice of the law's potential to generate savings. The report does acknowledge that some cost-control measures, including Medicare cuts and a tax on high-cost insurance, could create savings after 10 years, but it saw little likelihood of savings in the coming decade even though many of the costliest changes don't start until 2014.

Without cost controls, reform can't achieve the necessary and crucial long-term goals of providing affordable, high-quality health care to all Americans. Congress and the administration need to monitor the implementation of this law, misnamed the Affordable Health Care Act, and make changes as they are called for. It's unlikely that will be done by President Obama, who wanted this reform, apparently, at all costs. And changes will prove difficult in the Congress as well, given Democrats' loyalty to the legislation and Republicans' refusal to participate in any meaningful way to its development.

But failure to curb those costs and pay for the expansion of care makes it even more likely that this year's legislation will lead to very serious consequences for everyone.

icon url

AlpineBV_Miller

04/28/10 12:03 PM

#94888 RE: DewDiligence #94820

Fabulous, thank you.
icon url

DewDiligence

05/02/10 4:49 PM

#95086 RE: DewDiligence #94820

BMY was up 4% Thursday (a very big move for such a stable stock)
because the 2010 EPS hit from ObamaCare of $0.12 turned out to be
smaller than investors had feared. Investors had expected a bigger hit
because 2/3 of BMY’s sales come from the US and one of BMY’s biggest
drugs, Abilify, derives a high proportion of its sales from Medicaid.

Beyond the headline numbers, BMY’s earnings report contained good
news and bad news. The good news: BMY’s underlying business strength
would have caused 2010 EPS guidance to be raised by $0.05 if not for
ObamaCare; thus, the net cut to BMY’s 2010 EPS guidance was only $0.07
despite the $0.12 hit from ObamaCare. The bad news: the ObamaCare hit
will be twice as large in 2011 as in 2010, causing revenue to be clipped by
$600-800M. (See #msg-49486773 for a blow-by-blow description of why the
hit becomes much larger in 2011.)

http://www.zacks.com/stock/news/33554/Bristol-Myers+Tops+but+Trims

Bristol-Myers Tops but Trims

Thursday April 29, 2010, 1:51 pm EDT

Bristol-Myers Squibb Company (NYSE: BMY) earned 56 cents per share in the first quarter of fiscal 2010, far above the Zacks Consensus Estimate by 5 cents. The company had earned 42 cents per share in the year-ago quarter. However, the company has reduced its 2010 forecast prompted by costs associated with U.S. healthcare reform.

On a reported basis, Bristol-Myers earned 43 cents per share in the first quarter of 2010 as opposed to 33 cents in the comparable quarter of 2009.

Net sales in the reported quarter climbed 11.3% year-over-year to $4.81 billion. The favorable currency exchange rates favorably boosted revenues in the quarter by approximately 3%. The recently enacted healthcare reform has negatively impacted net sales in the reported quarter by 1%.

The jump in net sales for the reported quarter was primarily attributable to strong sales of Plavix, an anti-platelet blood thinner indicated to reduce the risk of heart attack in patients with atherosclerosis (the build-up of plaque and hardening of the arteries), and Baraclude for treating hepatitis B virus. In addition, Bristol reports robust sales of HIV treatment drugs Reyataz and Sustiva.

Global net sales of Plavix, co-marketed with Sanofi-Aventis (NYSE: SNY), climbed 16% year-over-year to $1.67 billion in the quarter. Worldwide sales of Sustiva in the quarter came in at $335 million, up 15%. Reyataz sales for the quarter stood at $373 million, up 16%, and Baraclude sales came in at $216 million, up 42%.

Global sales of Abilify, for the treatment of schizophrenia and depression, came in at $617 million, up 5% from the year-ago quarter. Sales of the rheumatoid arthritis drug Orencia stood at $169 million, up 36%, while the leukemia drug Sprycel registered sales of $131 million, up 49%. The global net sales of Ixempra for the reported quarter climbed 21% year-over-year to $29 million.

Cancer drug Erbitux generated sales of $166 million in the reported quarter, up 1%. Furthermore, Onglyza a type II diabetes treatment, co-developed with AstraZeneca plc (NYSE: AZN) contributed approximately $10 million to sales in the quarter. The gross margin as a percentage of net sales stood at 72.8% in the reported quarter.

Marketing, selling and administrative expenses were flat at $900 million in the reported quarter. Advertising and product promotion for the quarter came in at $212 million as against $248 million in the first quarter of 2009. Research and development expenses came in at $910 million, compared to $908 million in the year-ago quarter.

Bristol-Myers exited the quarter with $5.13 billion in cash and cash equivalents. The effective tax rate on earnings stood at 24.2% for the quarter as against 23% in the year-ago quarter.

Outlook Trimmed

Bristol-Myers has provided guidance for 2010. The company estimates healthcare reform to impact earnings by 12 cents in 2010. Bristol-Myers has trimmed its 2010 earnings (excluding special items) forecast by 5 cents to $2.10 per share - $2.20 per share as the impact of healthcare reform is expected to partially offset the strong underlying business and mitigating initiatives undertaken by Bristol-Myers. The company had projected 2010 earnings (excluding special items) in the range of $2.15 per share to $2.25 per share in January 2010.

The company updated its 2010 reported earnings guidance range to $1.84 to $1.94 per share. The forecast reflects higher manufacturing rationalization costs and a licensing transaction, in addition to the impact of the healthcare reform. The 2010 guidance assumes a mid-single-digit revenue growth.‹
icon url

DewDiligence

11/04/10 6:53 PM

#108111 RE: DewDiligence #94820

Big Pharma’s Midterm Blues

[It’s helpful to have #msg-49486773 handy while reading this article.]

http://online.wsj.com/article/SB10001424052748703805704575594443638093542.html

›NOVEMBER 4, 2010, 2:07 P.M. ET
By HESTER PLUMRIDGE

President Obama's health-care overhaul may have been one of the hottest topics on the midterm campaign trail, but his party's election losses scarcely made an impact on global pharmaceutical-stock valuations. The market clearly doesn't anticipate the new Congress will be able to derail Democrat plans, which already are starting to weigh on drug-company earnings. Combined with strong government head winds from Europe, it points to difficult times ahead for the industry.

The market may be underestimating the impact of the U.S. overhaul. Changes to U.S. Medicaid and Medicare programs are forcing firms to offer bigger rebates on their drugs already. Johnson & Johnson last month lowered its full-year sales forecasts after third quarter U.S. revenue disappointed. It isn't yet clear whether wider health-insurance enrollment will boost volumes sufficiently to offset lower prices. Goldman Sachs estimates the changes could shave an annual 5% off pharma operating profit until 2015.

With the US still the single biggest profit pool for drugs groups, that is a problem for the whole industry. U.S. giants such as Bristol-Myers Squibb, Pfizer and Johnson & Johnson derive around 55% of revenues from the U.S, European drugs majors around 40%. Meanwhile, Europe's austerity measures are biting into profits, too: German, Greek and Spanish governments all have cut prices they pay for drugs this year. Others, including France and Ireland, use Germany as a pricing benchmark.

Drug companies hope that what they lose on developed-market sales they can more than make up in emerging-market growth. New drug approvals to replace losses from those coming off patent also are key to pharma fortunes. More-diversified firms such as Abbott Laboratories and GlaxoSmithKline with nutrition and consumer health-care divisions could be better insulated from regulatory head winds than those without alternative revenue streams. Those with relatively low emerging-market exposures such as AstraZeneca are more likely to struggle.

But with the industry trading at just 10.5 times forecast 2011 earnings, well below the midteen average multiples enjoyed over the past decade, the market is predicting a bleak future. It will take more than an election to change that prognosis.‹
icon url

DewDiligence

08/16/11 8:25 AM

#125172 RE: DewDiligence #94820

Medicare/Medicaid drug rebates for 100 commonly prescribed branded drugs averaged 19% and 45%, respectively, according to HHS:

http://www.nytimes.com/2011/08/16/us/16drug.html
icon url

DewDiligence

11/28/11 10:19 AM

#131906 RE: DewDiligence #94820

Medicare “donut hole” factoids from 2011:

http://www.bostonglobe.com/news/nation/2011/11/28/medicare-drug-coverage-gap-shrinks/Qzbz5ZE3igW1DKlP0Uw1PL/story.html

The average beneficiary who falls into the coverage gap would have spent $1,504 this year on prescriptions. But due to discounts and other provisions in President Obama’s health care overhaul la, that cost fell to $901, according to Medicare’s Office of the Actuary, which handles economic estimates.

A 50 percent discount that the law secured from pharmaceutical companies on brand-name drugs yielded an average savings of $581. Medicare also picked up more of the cost of generic drugs, saving an additional $22.

… Medicare covers about 47 million older and disabled people, and about 9 in 10 have some kind of prescription plan. Most rely on the drug benefit, also known as Part D, which is delivered through private insurance plans.

…The coverage gap…starts after an individual beneficiary and his or her drug plan have spent $2,840 on medications for the year. Seniors are then on their own for the next $3,600. Once spending reaches about $6,440, Medicare’s catastrophic coverage kicks in and beneficiaries pay only a token amount.

icon url

DewDiligence

10/03/12 11:29 PM

#149977 RE: DewDiligence #94820

Can’t believe Jim Cramer thinks ObamaCare is good for Big Pharma/Big Bio (according to David Maris tweet). He ought to read #msg-49486773.
icon url

DewDiligence

07/30/13 10:46 PM

#164734 RE: DewDiligence #94820

Scott Gottlieb details the ‘340B’ hospital boondoggle:

http://online.wsj.com/article/SB10001424127887324110404578630522319113676.html

See #msg-49486773 for background info.